Soleno Capital Surpluse from 2010 to 2024

SLNO Stock  USD 57.78  3.15  5.77%   
Soleno Therapeutics Capital Surpluse yearly trend continues to be very stable with very little volatility. Capital Surpluse is likely to drop to about 149.3 M. During the period from 2010 to 2024, Soleno Therapeutics Capital Surpluse quarterly data regression pattern had sample variance of 5354.4 T and median of  140,494,976. View All Fundamentals
 
Capital Surpluse  
First Reported
2014-09-30
Previous Quarter
246 M
Current Value
248.4 M
Quarterly Volatility
60.9 M
 
Yuan Drop
 
Covid
Check Soleno Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Soleno Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.8 M, Interest Expense of 282.1 K or Selling General Administrative of 7.4 M, as well as many indicators such as Dividend Yield of 0.0, Ptb Ratio of 4.43 or Days Sales Outstanding of 139. Soleno financial statements analysis is a perfect complement when working with Soleno Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Soleno Therapeutics Correlation against competitors.
To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.

Latest Soleno Therapeutics' Capital Surpluse Growth Pattern

Below is the plot of the Capital Surpluse of Soleno Therapeutics over the last few years. It is Soleno Therapeutics' Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Soleno Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Capital Surpluse10 Years Trend
Slightly volatile
   Capital Surpluse   
       Timeline  

Soleno Capital Surpluse Regression Statistics

Arithmetic Mean137,343,775
Geometric Mean118,771,098
Coefficient Of Variation53.28
Mean Deviation62,272,180
Median140,494,976
Standard Deviation73,173,509
Sample Variance5354.4T
Range201.5M
R-Value0.89
Mean Square Error1239.5T
R-Squared0.79
Significance0.000011
Slope14,497,201
Total Sum of Squares74961.1T

Soleno Capital Surpluse History

2024149.3 M
2023262.1 M
2020227.9 M
2019172.7 M
2018157.4 M
2017140.5 M
2016101.7 M

About Soleno Therapeutics Financial Statements

Soleno Therapeutics investors utilize fundamental indicators, such as Capital Surpluse, to predict how Soleno Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Capital Surpluse262.1 M149.3 M

Pair Trading with Soleno Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Soleno Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Soleno Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Soleno Stock

  0.82MTEM Molecular TemplatesPairCorr
  0.72AGL agilon healthPairCorr
  0.7MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr
  0.68NKTX Nkarta IncPairCorr
  0.66VALN Valneva SE ADRPairCorr
The ability to find closely correlated positions to Soleno Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Soleno Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Soleno Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Soleno Therapeutics to buy it.
The correlation of Soleno Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Soleno Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Soleno Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Soleno Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Soleno Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Soleno Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Soleno Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Soleno Therapeutics Stock:
Check out the analysis of Soleno Therapeutics Correlation against competitors.
To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.
You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Soleno Therapeutics. If investors know Soleno will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Soleno Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.79)
Return On Assets
(0.48)
Return On Equity
(0.91)
The market value of Soleno Therapeutics is measured differently than its book value, which is the value of Soleno that is recorded on the company's balance sheet. Investors also form their own opinion of Soleno Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Soleno Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Soleno Therapeutics' market value can be influenced by many factors that don't directly affect Soleno Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Soleno Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Soleno Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Soleno Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.